Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

伊瓦卡夫托 医学 囊性纤维化 囊性纤维化跨膜传导调节器 内科学 临床终点 随机对照试验 临床试验
作者
Ahmet Uluer,Gordon MacGregor,Pilar Azevedo,V. Indihar,Claire Keating,Marcus Mall,Edward F. McKone,Bonnie W. Ramsey,Steven M. Rowe,Ronald C. Rubenstein,Jennifer L. Taylor‐Cousar,Elizabeth Tullis,Lael M. Yonker,Chenghao Chu,Anna Lam,Nitin Nair,Patrick R. Sosnay,Simon Tian,Fredrick Van Goor,Lakshmi Viswanathan,David Waltz,Linda T. Wang,Yingmei Xi,Joanne Billings,Alexander Horsley,Alexander Horsley,Edward F. Nash,Marleen Bakker,Renske van der Meer,Petrus Merkus,Christof J. Majoor,Karen McCoy,Joanne Billings,Krishna Pancham,James Tolle,Bryon Quick,Ahmet Uluer,Emily DiMango,Adupa P. Rao,Santiago Reyes,Ross C. Klingsberg,Celeste Barreto,Victor E. Ortega,Donna Beth Willey‐Courand,C. Schwarz,Sivagurunathan Sutharsan,Rainald Fischer,Jane Davies,J. Duckers,Alexander Horsley,Simon Doe,Edward F. Nash,Marleen Bakker,Harry G.M. Heijerman,Renske van der Meer,Petrus Merkus,Christof J. Majoor,George M. Solomon,Christian A. Merlo,Jennifer Griffonnet,Joseph M. Pilewski,Jordan Dunitz,Saba Sheikh,Ronald C. Rubenstein,Daniel Rosenbluth,Theodore G. Liou,Maria Veronica Indihar,Krishna Pancham,Lael M. Yonker,Samya Z. Nasr,Jennifer Griffonnet,Cynthia Brown,Gregory S. Sawicki,Jennifer Ruddy,Emily DiMango,Bryan Garcia,Andrew T. Braun,Alex H. Gifford,Nighat Mehdi,Maria Tupayachi Ortiz,Raksha Jain,Francisco J. Calimano,Jimmy Johannes,Cori Daines,Jason Fullmer,Joel Mermis,Christopher Barrios,Ngoc P. Ly,Brian Casserly,Stephan Eisenmann,Helge Hebestreit,Alexander Kiefer,Sivagurunathan Sutharsan,Rainald Fischer,Gordon MacGregor,Daniel Peckham,M.J. Ledson,Eva Van Braeckel,Petrus Merkus,Noel G. McElvaney,Edward F. McKone,Barry J. Plant,Lucy Burr,Daniel J. Smıth,Peter G. Middleton,John W. Wilson
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:11 (6): 550-562 被引量:20
标识
DOI:10.1016/s2213-2600(22)00504-5
摘要

Background Elexacaftor-tezacaftor-ivacaftor has been shown to be safe and efficacious in people with cystic fibrosis and at least one F508del allele.Our aim was to identify a novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination capable of further increasing CFTR-mediated chloride transport, with the potential for once-daily dosing. MethodsWe conducted two phase 2 clinical trials to assess the safety and efficacy of a once-daily combination of vanzacaftor-tezacaftor-deutivacaftor in participants with cystic fibrosis who were aged 18 years or older.A phase 2 randomised, double-blind, active-controlled study (VX18-561-101; April 17, 2019, to Aug 20, 2020) was carried out to compare deutivacaftor monotherapy with ivacaftor monotherapy in participants with CFTR gating mutations, following a 4-week ivacaftor monotherapy run-in period.Participants were randomly assigned to receive either ivacaftor 150 mg every 12 h, deutivacaftor 25 mg once daily, deutivacaftor 50 mg once daily, deutivacaftor 150 mg once daily, or deutivacaftor 250 mg once daily in a 1:1:2:2:2 ratio.The primary endpoint was absolute change in ppFEV₁ from baseline at week 12.A phase 2 randomised, double-blind, controlled, proof-of-concept study of vanzacaftor-tezacaftor-deutivacaftor (VX18-121-101; April 30, 2019, to Dec 10, 2019) was conducted in participants with cystic fibrosis and heterozygous for F508del and a minimal function mutation (F/MF genotypes) or homozygous for F508del (F/F genotype).Participants with F/MF genotypes were randomly assigned 1:2:2:1 to receive either 5 mg, 10 mg, or 20 mg of vanzacaftor in combination with tezacaftor-deutivacaftor or a triple placebo for 4 weeks, and participants with the F/F genotype were randomly assigned 2:1 to receive either vanzacaftor (20 mg)-tezacaftor-deutivacaftor or tezacaftor-ivacaftor active control for 4 weeks, following a 4-week tezacaftor-ivacaftor run-in period.Primary endpoints for part 1 and part 2 were safety and tolerability and absolute change in ppFEV 1 from baseline to day 29.Secondary efficacy endpoints were absolute change from baseline at day 29 in sweat chloride concentrations and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score.These clinical trials are registered with ClinicalTrials.gov,NCT03911713 and NCT03912233, and are complete.Findings In study VX18-561-101, participants treated with deutivacaftor 150 mg once daily (n=23) or deutivacaftor 250 mg once daily (n=24) had mean absolute changes in ppFEV₁ of 3•1 percentage points (95% CI -0•8 to 7•0) and 2•7 percentage points (-1•0 to 6•5) from baseline at week 12, respectively, versus -0•8 percentage points (-6•2 to 4•7) with ivacaftor 150 mg every 12 h (n=11); the deutivacaftor safety profile was consistent with the established safety profile of ivacaftor 150 mg every 12 h.In study VX18-121-101, participants with F/MF genotypes treated with vanzacaftor (5 mg)-tezacaftor-deutivacaftor (n=9), vanzacaftor (10 mg)-tezacaftor-deutivacaftor (n=19), vanzacaftor (20 mg)-tezacaftor-deutivacaftor (n=20), and placebo (n=10) had mean changes relative to baseline at day 29 in ppFEV₁ of 4•6 percentage points (-1•3 to 10•6), 14•2 percentage points (10•0 to 18•4), 9•8 percentage points (5•7 to 13•8), and 1•9 percentage points (-4•1 to 8•0), respectively, in sweat chloride concentration of -42•8 mmol/L (-51•7 to -34•0), -45•8 mmol/L (95% CI -51•9 to -39•7), -49•5 mmol/L (-55•9 to -43•1), and 2•3 mmol/L (-7•0 to 11•6), respectively, and in CFQ-R respiratory domain score of 17•6 points (3•5 to 31•6), 21•2 points (11•9 to 30•6), 29•8 points (21•0 to 38•7), and 3•3 points (-10•1 to 16•6), respectively.Participants with the F/F genotype treated with vanzacaftor (20 mg)-tezacaftor-deutivacaftor (n=18) and tezacaftor-ivacaftor (n=10) had mean changes relative to baseline (taking tezacaftor-ivacaftor) at day 29 in ppFEV₁ of 15•9 percentage points (11•3 to 20•6) and -0•1 percentage points (-6•4 to 6•1), respectively, in sweat chloride concentration of -45•5 mmol/L (-49•7 to -41•3) and -2•6 mmol/L (-8•2 to 3•1), respectively, and in CFQ-R respiratory domain score of 19•4 points (95% CI 10•5 to 28•3) and -5•0 points (-16•9 to 7•0), respectively.The most common adverse events overall were cough, increased sputum, and headache.One participant in the vanzacaftor-tezacaftor-deutivacaftor group had a serious adverse event of infective pulmonary exacerbation and another participant had a serious rash event that led to treatment discontinuation.For most participants, adverse events were mild or moderate in severity.www.thelancet.com/respiratory

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木子发布了新的文献求助10
刚刚
钟嘉霖完成签到,获得积分10
刚刚
小小发布了新的文献求助100
1秒前
Maestro_S的应助被Kenny采纳,获得10
1秒前
天际小山完成签到,获得积分10
3秒前
3秒前
xing发布了新的文献求助10
3秒前
4秒前
丁鹏笑完成签到 ,获得积分0
4秒前
孟昊如完成签到,获得积分10
4秒前
null的应助被aaa采纳,获得10
5秒前
6秒前
8秒前
英姑的应助被aoa采纳,获得10
9秒前
10秒前
10秒前
清汐完成签到 ,获得积分10
10秒前
那当然完成签到 ,获得积分10
11秒前
11秒前
苗浩阳完成签到,获得积分10
13秒前
Shirley发布了新的文献求助10
14秒前
ChaseY完成签到 ,获得积分10
15秒前
xing发布了新的文献求助10
15秒前
科目三的应助被sinmon采纳,获得10
16秒前
WK完成签到,获得积分10
16秒前
17秒前
执着的青烟完成签到,获得积分10
17秒前
17秒前
17秒前
ice完成签到 ,获得积分10
18秒前
舔舔给舔舔的求助进行了留言
18秒前
19秒前
19秒前
20秒前
20秒前
Owen的应助被aaa采纳,获得30
20秒前
casual完成签到,获得积分10
21秒前
树袋熊完成签到,获得积分10
21秒前
yitinti完成签到,获得积分10
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160961
求助须知:如何正确求助?哪些是违规求助? 9555819
关于积分的说明 21730291
捐赠科研通 7750940
什么是DOI,文献DOI怎么找? 3427477
关于科研通互助平台的介绍 2552515
邀请新用户注册赠送积分活动 2471912